, Volume 33, Issue 2, pp 173–181 | Cite as

A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males

  • Sang-Heon Cho
  • Seunghoon Han
  • Jong-Lyul Ghim
  • Moon-Suk Nam
  • Sunyoung Yu
  • Taehong Park
  • Sinhye Kim
  • Jihun Bae
  • Jae-Gook ShinEmail author
Original Research Article



CT-P16 is a candidate biosimilar of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor that is used in the treatment of a range of advanced solid cancers.


The objective of this study was to demonstrate the pharmacokinetic equivalence of CT-P16 and European Union (EU)-approved bevacizumab (EU-bevacizumab) and US-licensed bevacizumab (US-bevacizumab) reference products.


In this double-blind, parallel-group phase I trial ( identifier NCT03247673), healthy adult males were randomized (1:1:1) to receive a single dose of CT-P16 5 mg/kg, EU-bevacizumab 5 mg/kg, or US-bevacizumab 5 mg/kg. Primary study endpoints were area under the concentration–time curve (AUC) from time zero to infinity (AUC), AUC from time zero to the last quantifiable concentration (AUClast), and maximum serum concentration (Cmax). Pharmacokinetic equivalence was shown if the 90% confidence intervals (CIs) of the geometric mean (GM) ratios of the AUC, AUClast, and Cmax were within the predefined bioequivalence margin of 80–125%. Safety and immunogenicity were also evaluated.


A total of 144 subjects were randomized: 47 to CT-P16, 49 to EU-bevacizumab, and 48 to US-bevacizumab. The 90% CIs for the GM ratios of AUC, AUClast, and Cmax for CT-P16/EU-bevacizumab, CT-P16/US-bevacizumab, and EU-bevacizumab/US-bevacizumab comparisons were all within the bioequivalence margin. Mean serum concentration–time profiles, secondary pharmacokinetic parameters, and safety and immunogenicity profiles were comparable across all three treatment groups.


CT-P16 demonstrated pharmacokinetic equivalence to EU-bevacizumab and US-bevacizumab. Safety and immunogenicity profiles were similar for CT-P16, EU-bevacizumab, and US-bevacizumab. These data support the further clinical evaluation of CT-P16 as a bevacizumab biosimilar.

Clinical Trials Registration




We thank all study investigators, staff, and subjects who contributed to this study. Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking, and referencing) was provided by Emma Evans Ph.D., CMPP and Rick Flemming Ph.D., CMPP at Aspire Scientific Limited (Bollington, UK), and funded by CELLTRION, Inc. (Incheon, Republic of Korea).

Author Contributions

S-HC, SH, SY, TP, M-SN, and J-GS were involved in the conception and/or design of this study. J-LG, SY, TP, SK, and JB were involved in the acquisition, analysis, and/or interpretation of the data. All authors contributed to development of the manuscript and approved the final version for submission.

Compliance with Ethical Standards


This study was sponsored by CELLTRION, Inc. (Incheon, Republic of Korea).

Conflict of Interest

SY, TP, SK, and JB are employees of CELLTRION, Inc. SY has stock in CELLTRION, Inc. S-HC, SH, J-LG, M-SN, and J-GS have no conflicts of interest to declare.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

40259_2019_340_MOESM1_ESM.docx (60 kb)
Supplementary material 1 (DOCX 60 kb)


  1. 1.
    Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–17.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Midgley R, Kerr D. Bevacizumab–current status and future directions. Ann Oncol. 2005;16(7):999–1004.CrossRefPubMedGoogle Scholar
  3. 3.
    Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem. 2006;13(16):1845–57.CrossRefPubMedGoogle Scholar
  4. 4.
    Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15(1):102–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Kazazi-Hyseni F, Beijnen JH, Schellens JH. TEST Bevacizumab. Oncologist. 2010;15(8):819–25.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of bevacizumab (Avastin) on survival in metastatic solid tumors–a meta-analysis and systematic review. PLoS One. 2013;8(1):e51780.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    European Medicines Agency. Avastin Summary of Product Characteristics. 2018. Accessed 22 Nov 2018.
  8. 8.
    United States Food and Drug Administration. Avastin prescribing information. 2018. Accessed 22 Nov 2018.
  9. 9.
    Buske C, Ogura M, Kwon HC, Yoon SW. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol. 2017;13(15s):5–16.CrossRefPubMedGoogle Scholar
  10. 10.
    European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. Accessed 22 Nov 2018.
  11. 11.
    United States Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. 2015. Accessed 22 Nov 2018.
  12. 12.
    Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839–46.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Markus R, Chow V, Pan Z, Hanes V. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2017;80(4):755–63.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wynne C, Schwabe C, Batra SS, Lopez-Lazaro L, Kankanwadi S. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects. Br J Clin Pharmacol. 2018;84(10):2352–64.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang H, Li Q, Zhu X, Li C, Li X, Liu C, et al. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. Cancer Chemother Pharmacol. 2018;82(4):615–23.CrossRefPubMedGoogle Scholar
  16. 16.
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. London, January 20. CPMP/EWP/QWP/1401/98 Rev. 1/Corr**. 2010. Accessed 12 Oct 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Inha University HospitalInha University School of MedicineIncheonRepublic of Korea
  2. 2.The Catholic University of Korea Seoul St. Mary’s HospitalSeoulRepublic of Korea
  3. 3.Inje University and Inje University Busan Paik HospitalBusanRepublic of Korea
  4. 4.CELLTRION, Inc.IncheonRepublic of Korea

Personalised recommendations